ACET [NASD]
Adicet Bio, Inc.
Index- P/E- EPS (ttm)-1.37 Insider Own0.90% Shs Outstand40.08M Perf Week4.32%
Market Cap612.10M Forward P/E- EPS next Y-2.11 Insider Trans-23.33% Shs Float38.27M Perf Month6.89%
Income-47.70M PEG- EPS next Q-0.30 Inst Own92.50% Short Float7.96% Perf Quarter-14.03%
Sales33.90M P/S18.06 EPS this Y60.00% Inst Trans19.91% Short Ratio5.87 Perf Half Y-20.92%
Book/sh7.32 P/B2.08 EPS next Y-64.80% ROA-15.10% Target Price27.64 Perf Year102.67%
Cash/sh- P/C- EPS next 5Y29.10% ROE-17.00% 52W Range7.13 - 21.17 Perf YTD-13.09%
Dividend- P/FCF- EPS past 5Y- ROI-20.20% 52W High-28.20% Beta2.22
Dividend %- Quick Ratio16.10 Sales past 5Y- Gross Margin- 52W Low113.18% ATR1.08
Employees86 Current Ratio16.10 Sales Q/Q- Oper. Margin- RSI (14)51.97 Volatility8.46% 8.10%
OptionableYes Debt/Eq0.00 EPS Q/Q-64.90% Profit Margin- Rel Volume1.07 Prev Close15.25
ShortableYes LT Debt/Eq0.00 EarningsAug 11 AMC Payout- Avg Volume518.85K Price15.20
Recom1.50 SMA200.09% SMA50-1.68% SMA2003.13% Volume554,491 Change-0.33%
Sep-21-22Initiated JP Morgan Overweight $23
Mar-31-22Initiated SMBC Nikko Outperform $28
Mar-08-22Initiated Truist Buy $30
Mar-04-22Initiated Jefferies Buy $27
May-18-21Initiated BTIG Research Buy $34
Apr-23-21Initiated H.C. Wainwright Buy $27
Apr-14-21Initiated Canaccord Genuity Buy $28
Apr-08-21Initiated Guggenheim Buy $22
Nov-04-20Initiated B. Riley Securities Buy $30
Oct-27-20Initiated JMP Securities Mkt Outperform $30
Oct-16-20Initiated Wedbush Outperform $25
Oct-05-22 08:00AM
Sep-30-22 06:59PM
Sep-26-22 06:26AM
Sep-07-22 04:10PM
Aug-31-22 05:30PM
06:16AM Loading…
Aug-16-22 06:16AM
Aug-10-22 07:00AM
Aug-01-22 04:10PM
Jul-29-22 06:05PM
Jul-01-22 04:10PM
Jun-21-22 04:10PM
Jun-06-22 07:00AM
Jun-03-22 04:10PM
May-26-22 05:00PM
May-18-22 04:00PM
08:21AM Loading…
May-15-22 08:21AM
May-12-22 04:10PM
11:14AM
May-05-22 07:00AM
May-04-22 04:10PM
Apr-27-22 10:00AM
Apr-19-22 07:00AM
Apr-07-22 04:10PM
Apr-01-22 04:10PM
Mar-22-22 12:47PM
Mar-15-22 04:00PM
07:25AM
Mar-04-22 04:00PM
Feb-02-22 07:00AM
Dec-10-21 04:01PM
05:49PM Loading…
Dec-09-21 05:49PM
Dec-08-21 01:13AM
Dec-07-21 04:16PM
Dec-06-21 07:00AM
Nov-29-21 07:00AM
Nov-20-21 06:00AM
Nov-18-21 07:00AM
Nov-12-21 07:00AM
Nov-10-21 04:01PM
Nov-08-21 07:00AM
Nov-04-21 09:00AM
Oct-26-21 03:00AM
Oct-12-21 04:10PM
Oct-04-21 07:00AM
Sep-13-21 08:00AM
08:00AM
Sep-02-21 04:53PM
Aug-12-21 04:01PM
Aug-02-21 07:00AM
Jul-30-21 10:35AM
Jul-15-21 07:00AM
Jun-28-21 07:00AM
May-18-21 04:10PM
May-17-21 07:01AM
Apr-29-21 07:00AM
Apr-15-21 07:00AM
Apr-13-21 07:00AM
Mar-11-21 04:10PM
Mar-10-21 07:00AM
Mar-04-21 04:01PM
Feb-16-21 07:00AM
Feb-11-21 07:00AM
Feb-10-21 07:51AM
Feb-09-21 04:04PM
Jan-07-21 07:00AM
Dec-15-20 11:19PM
Dec-08-20 07:00AM
Dec-07-20 11:37PM
Dec-01-20 07:00AM
Nov-06-20 07:00AM
Nov-05-20 04:10PM
Oct-26-20 04:10PM
Oct-22-20 07:00AM
Oct-01-20 04:10PM
Sep-22-20 10:42PM
Sep-21-20 07:00AM
Sep-18-20 04:10PM
Sep-16-20 07:00AM
Sep-15-20 04:10PM
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schor ChenPresident & CEOSep 14Sale18.0095217,136138,737Sep 16 05:51 PM
Schor ChenPresident & CEOSep 13Sale18.013,37160,713139,689Sep 13 04:59 PM
Schor ChenPresident & CEOSep 12Sale16.7766,9471,122,9070Sep 13 04:59 PM
Schor ChenPresident & CEOSep 09Sale16.518,094133,60166,747Sep 13 04:59 PM
Aftab BlakeChief Scientific OfficerAug 03Sale18.006,968125,42438,967Aug 05 06:43 PM
Aftab BlakeChief Scientific OfficerAug 01Sale16.646,968115,94845,935Aug 03 04:16 PM
Aftab BlakeChief Scientific OfficerJul 05Sale14.501,36319,76452,903Jul 07 05:12 PM
Galimi FrancescoSVP & Chief Medical OfficerApr 04Option Exercise13.917,979110,95665,953Apr 05 06:23 PM
Galimi FrancescoSVP & Chief Medical OfficerApr 04Sale21.007,979167,55959,917Apr 05 06:23 PM
Galimi FrancescoSVP & Chief Medical OfficerApr 01Option Exercise5.977,62145,49767,538Apr 05 06:23 PM
Galimi FrancescoSVP & Chief Medical OfficerApr 01Sale21.007,621160,04159,917Apr 05 06:23 PM
Jakobovits AyaDirectorMar 09Sale14.004,00056,000356,343Mar 11 04:08 PM
Jakobovits AyaDirectorFeb 16Sale14.834,00059,328358,343Feb 17 06:10 PM
Jakobovits AyaDirectorFeb 09Sale14.038,000112,239360,343Feb 14 05:28 PM
Jakobovits AyaDirectorJan 05Sale16.924,00067,663364,343Feb 14 05:28 PM
Jakobovits AyaDirectorJan 03Sale18.0212,000216,256366,343Feb 14 05:28 PM
Sinclair AndrewDirectorDec 08Buy14.00500,0007,000,0002,140,721Dec 10 05:30 PM